Brain metastases in gastroesophageal cancers—an underestimated complication
Tóm tắt
Brain metastases represent a severe complication in many gastrointestinal malignancies especially those arising from the upper gastrointestinal tract, including cancer of the esophagus, gastroesophageal junction, and stomach (GEC). However, there is little knowledge about the onset or potential risk factors for brain metastases (BRMs) in upper gastrointestinal cancers resulting in a lack of screening guidelines for BRMs. We analyzed 827 patients from our cancer registry suffering from gastroesophageal cancer (GEC) and treated at the University Medical Center Göttingen between January 2013 and December 2019 for the presence of BRMs. From 827 patients with GEC we found 54 patients with BRMs, resulting in an incidence of 6.5%. BRMs are more frequent in male patients (90.74% vs 9.26%, p = 0.0051) and in adenocarcinomas (90.74% vs 9.26%, p = 0.0117). Mean duration for the onset of BRMs from initial cancer diagnoses was 20.9 months in limited disease (curative approach) and 9.3 months in advanced disease (palliative approach) (p = 0.0026). However, early detection of BRMs is a prognostic factor since patients with successful resection of BRMs have a better prognosis compared to those with unresectable BRMs (5.93 vs 2.07 months, p = 0.0091). In this single-center retrospective study, brain metastases (BRMs) occur with a high frequency (6.5%) in gastroesophageal cancer (GEC), significantly more often in male patients and adenocarcinomas. Since survival of these patients considerably correlates with successful BRMs resection, our observations propose further prospective trails to validate our hypothesis and ultimately the implementation of routine screening procedures to detect asymptomatic brain metastases.
Tài liệu tham khảo
Global Burden of Disease Cancer Collaboration. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–48. https://doi.org/10.1001/jamaoncol.2016.5688.
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.
Petrelli F. Prognostic value of diffuse versus intestinal histotype in patients with gastric cancer: a systematic review and meta-analysis. J Gastrointest Oncol. 2017;8(1):148–63. https://doi.org/10.21037/jgo.2017.01.10.
Riihimäki M, Hemminki A, Sundquist K, Sundquist J, Hemminki K. Metastatic spread in patients with gastric cancer. Oncotarget. 2016;7(32):52307–16. https://doi.org/10.18632/oncotarget.10740.
Sexton RE, Alhallak MN, Diab M, Azmi AS. Gastric cancer: a comprehensive review of current and future treatment strategies. Cancer Metastasis Rev 2020;39(4):1179–1203. https://doi.org/10.1007/s10555-020-09925-3.
Yamada Y. Phase III study comparing triplet chemotherapy with S-1 and cisplatin plus docetaxel versus doublet chemotherapy with S-1 and cisplatin for advanced gastric cancer (JCOG1013). JCO. 2018;36(15 suppl):4009. https://doi.org/10.1200/JCO.2018.36.15_suppl.4009.
Muro K. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic oesophageal cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30(1):34–43. https://doi.org/10.1093/annonc/mdy498.
Wilke H. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35. https://doi.org/10.1016/S1470-2045(14)70420-6.
Smyth EC, Gambardella V, Cervantes A, Fleitas T. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol. 2021;32(5):590–9. https://doi.org/10.1016/j.annonc.2021.02.004.
Davis FG, Dolecek TA, McCarthy BJ, Villano JL. Toward determining the lifetime occurrence of metastatic brain tumors estimated from 2007 United States cancer incidence data. Neuro Oncol. 2012;14(9):1171–7. https://doi.org/10.1093/neuonc/nos152.
Cagney DN. Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017;19(11):1511–21. https://doi.org/10.1093/neuonc/nox077.
Singh R. Epidemiology of synchronous brain metastases. Neurooncol Adv. 2020;2(1):vdaa041. https://doi.org/10.1093/noajnl/vdaa041.
Welch G. Incidence of brain metastasis from esophageal cancer. Dis Esophagus. 2017;30(9):1–6. https://doi.org/10.1093/dote/dox071.
Harada K. Brain metastases in patients with upper gastrointestinal cancer is associated with proximally located adenocarcinoma and lymph node metastases. Gastric Cancer. 2020;23(5):904–12. https://doi.org/10.1007/s10120-020-01075-3.
Kothari N. Outcomes in patients with brain metastasis from esophageal carcinoma. J Gastrointest Oncol. 2016;7(4):562–9. https://doi.org/10.21037/jgo.2016.03.12.
Wadhwa R. Incidence of brain metastases after trimodality therapy in patients with esophageal or gastroesophageal cancer: implications for screening and surveillance. Oncology. 2013;85(4):204–7. https://doi.org/10.1159/000354736.
Mönig S. S3-Leitlinie Magenkarzinom-Diagnostik und Therapie der Adenokarzinome des Magens und ösophagogastralen Übergangs: Version 20–August 2019. AWMF-Registernummer: 032/009OL. Chirurg. 2020;91(1):37–40. https://doi.org/10.1007/s00104-020-01112-y.
Porschen K. S3-Leitlinie - Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus: Langversion 2.0 - Dezember 2018 AWMF-Registernummer: 021/023OL. Z Gastroenterol. 2019;57(03):336–418. https://doi.org/10.1055/a-0833-5712.
Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D. Oesophageal cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:50–7. https://doi.org/10.1093/annonc/mdw329.
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:38–49. https://doi.org/10.1093/annonc/mdw350.
Weinberg JS, Suki D, Hanbali F, Cohen ZR, Lenzi R, Sawaya R. Metastasis of esophageal carcinoma to the brain. Cancer. 2003;98(9):1925–33. https://doi.org/10.1002/cncr.11737.
Ogawa K. Brain metastases from esophageal carcinoma: natural history, prognostic factors, and outcome. Cancer. 2002;94(3):759–64. https://doi.org/10.1002/cncr.10271.
Song Z, Lin B, Shao L, Zhang Y. Brain metastases from esophageal cancer: clinical review of 26 cases. World Neurosurg. 2014;81(1):131–5. https://doi.org/10.1016/j.wneu.2013.02.058.
Valiente M. Serpins promote cancer cell survival and vascular co-option in brain metastasis. Cell. 2014;156(5):1002–16. https://doi.org/10.1016/j.cell.2014.01.040.
Fidler IJ. The biology of brain metastasis: challenges for therapy. Cancer J. 2015;21(4):284–93. https://doi.org/10.1097/PPO.0000000000000126.
Limon D. Brain metastasis in gastroesophageal adenocarcinoma and HER2 status. J Neurooncol. 2018;138(2):315–20. https://doi.org/10.1007/s11060-018-2798-4.
Karamchandani MM, Ganti T, Jaiswal S, Wu JK, Saif MW. A rare occurrence of isolated brain metastases from gastric cancer. Case Rep Med. 2019;2019:1–5. https://doi.org/10.1155/2019/8075421.